Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 17-Apr-24 7:08 PM View:  | Vogt Frederick G Interim CEO & General Counsel | Iovance Biotherapeutics, Inc. (IOVA) | 15-Apr-24 | Option Exercise | 20,834 | -- | -- | 16% 129.35K to 150.19K | |
| 17-Apr-24 7:07 PM View: | Bilinsky Igor Chief Operating Officer | Iovance Biotherapeutics, Inc. (IOVA) | 15-Apr-24 | Payment of Exercise | 1,427 | $11.89 | $16,967.00 | (4%) 39.45K to 38.03K | |
| 17-Apr-24 7:07 PM View: | Bilinsky Igor Chief Operating Officer | Iovance Biotherapeutics, Inc. (IOVA) | 15-Apr-24 | Option Exercise | 2,812 | -- | -- | 8% 36.64K to 39.45K | |
| 17-Apr-24 7:07 PM View: | Graf Finckenstein Friedrich Chief Medical Officer | Iovance Biotherapeutics, Inc. (IOVA) | 15-Apr-24 | Payment of Exercise | 1,427 | $11.89 | $16,967.00 | (3%) 43.99K to 42.56K | |
| 17-Apr-24 7:08 PM View: | Vogt Frederick G Interim CEO & General Counsel | Iovance Biotherapeutics, Inc. (IOVA) | 15-Apr-24 | Payment of Exercise | 8,851 | $11.89 | $105,238.00 | (6%) 150.19K to 141.33K | |
| 17-Apr-24 7:07 PM View: | Graf Finckenstein Friedrich Chief Medical Officer | Iovance Biotherapeutics, Inc. (IOVA) | 15-Apr-24 | Option Exercise | 2,812 | -- | -- | 7% 41.18K to 43.99K | |
| 06-Mar-24 10:00 PM View: | Graf Finckenstein Friedrich Chief Medical Officer | Iovance Biotherapeutics, Inc. (IOVA) | 04-Mar-24 | Option Exercise | 15,623 | -- | -- | 46% 33.61K to 49.23K | |
| 06-Mar-24 10:00 PM View: | Vogt Frederick G Interim CEO & General Counsel | Iovance Biotherapeutics, Inc. (IOVA) | 04-Mar-24 | Option Exercise | 41,662 | -- | -- | 42% 99.14K to 140.8K | |
| 06-Mar-24 10:00 PM View: | Bilinsky Igor Chief Operating Officer | Iovance Biotherapeutics, Inc. (IOVA) | 04-Mar-24 | Payment of Exercise | 7,287 | $16.96 | $123,588.00 | (17%) 43.93K to 36.64K | |
| 06-Mar-24 10:00 PM View: | Bilinsky Igor Chief Operating Officer | Iovance Biotherapeutics, Inc. (IOVA) | 04-Mar-24 | Option Exercise | 14,061 | -- | -- | 47% 29.87K to 43.93K | |
| 06-Mar-24 10:00 PM View: | Graf Finckenstein Friedrich Chief Medical Officer | Iovance Biotherapeutics, Inc. (IOVA) | 04-Mar-24 | Payment of Exercise | 8,053 | $16.96 | $136,579.00 | (16%) 49.23K to 41.18K | |
| 06-Mar-24 10:00 PM View: | Vogt Frederick G Interim CEO & General Counsel | Iovance Biotherapeutics, Inc. (IOVA) | 04-Mar-24 | Payment of Exercise | 11,449 | $16.96 | $194,175.00 | (8%) 140.8K to 129.35K | |
| 20-Feb-24 7:52 PM View: | McPeak Merrill A/ Director | Iovance Biotherapeutics, Inc. (IOVA) | 20-Feb-24 | Private Purchase | 250,000 | $9.15 | $2,287,500.00 | 78% 318.78K to 568.78K | |
| 20-Feb-24 4:11 PM View: | Rothbaum Wayne P. Director | Iovance Biotherapeutics, Inc. (IOVA) | 20-Feb-24 | Private Purchase | 5,000,000 | $9.15 | $45,750,000.00 | 22% 23.07M to 28.07M | |
| 20-Feb-24 4:21 PM View: | Dukes Iain D. Director | Iovance Biotherapeutics, Inc. (IOVA) | 20-Feb-24 | Private Purchase | 32,000 | $9.15 | $292,800.00 | 145% 22.0K to 54.0K | |
| 18-Jan-24 6:07 PM View: | Bilinsky Igor Chief Operating Officer | Iovance Biotherapeutics, Inc. (IOVA) | 16-Jan-24 | Option Exercise | 2,813 | -- | -- | 10% 28.63K to 31.44K | |
| 18-Jan-24 6:09 PM View: | Graf Finckenstein Friedrich Chief Medical Officer | Iovance Biotherapeutics, Inc. (IOVA) | 16-Jan-24 | Payment of Exercise | 1,577 | $8.37 | $13,199.50 | (4%) 35.18K to 33.61K | |
| 18-Jan-24 6:09 PM View: | Vogt Frederick G Interim CEO & General Counsel | Iovance Biotherapeutics, Inc. (IOVA) | 16-Jan-24 | Payment of Exercise | 6,530 | $8.37 | $54,656.10 | (6%) 105.67K to 99.14K | |
| 18-Jan-24 6:09 PM View: | Graf Finckenstein Friedrich Chief Medical Officer | Iovance Biotherapeutics, Inc. (IOVA) | 16-Jan-24 | Option Exercise | 2,813 | -- | -- | 9% 32.37K to 35.18K | |
| 18-Jan-24 6:09 PM View: | Vogt Frederick G Interim CEO & General Counsel | Iovance Biotherapeutics, Inc. (IOVA) | 16-Jan-24 | Option Exercise | 20,834 | -- | -- | 25% 84.83K to 105.67K | |
| 18-Jan-24 6:07 PM View: | Bilinsky Igor Chief Operating Officer | Iovance Biotherapeutics, Inc. (IOVA) | 16-Jan-24 | Payment of Exercise | 1,577 | $8.37 | $13,199.50 | (5%) 31.44K to 29.87K | |
| 18-Oct-23 8:03 PM View: | Graf Finckenstein Friedrich Chief Medical Officer | Iovance Biotherapeutics, Inc. (IOVA) | 16-Oct-23 | Payment of Exercise | 1,395 | $3.57 | $4,980.15 | (4%) 33.77K to 32.37K | |
| 18-Oct-23 8:05 PM View: | Vogt Frederick G Interim CEO & General Counsel | Iovance Biotherapeutics, Inc. (IOVA) | 16-Oct-23 | Payment of Exercise | 8,851 | $3.57 | $31,598.10 | (9%) 93.69K to 84.83K | |
| 18-Oct-23 8:04 PM View: | Bilinsky Igor Chief Operating Officer | Iovance Biotherapeutics, Inc. (IOVA) | 16-Oct-23 | Option Exercise | 2,813 | -- | -- | 10% 27.21K to 30.03K | |
| 18-Oct-23 8:04 PM View: | Bilinsky Igor Chief Operating Officer | Iovance Biotherapeutics, Inc. (IOVA) | 16-Oct-23 | Payment of Exercise | 1,395 | $3.57 | $4,980.15 | (5%) 30.03K to 28.63K | |
| 18-Oct-23 8:03 PM View: | Graf Finckenstein Friedrich Chief Medical Officer | Iovance Biotherapeutics, Inc. (IOVA) | 16-Oct-23 | Option Exercise | 2,813 | -- | -- | 9% 30.95K to 33.77K | |
| 18-Oct-23 8:05 PM View: | Vogt Frederick G Interim CEO & General Counsel | Iovance Biotherapeutics, Inc. (IOVA) | 16-Oct-23 | Option Exercise | 20,835 | -- | -- | 29% 72.85K to 93.69K | |
| 19-Sep-23 4:30 PM View: | McPeak Merrill A/ Director | Iovance Biotherapeutics, Inc. (IOVA) | 18-Sep-23 | Private Purchase | 10,000 | $5.56 | $55,600.00 | 3% 308.78K to 318.78K | |
| 15-Sep-23 6:12 PM View: | Rothbaum Wayne P. Director | Iovance Biotherapeutics, Inc. (IOVA) | 15-Sep-23 | Private Purchase | 5,000,000 | $5.30 | $26,500,000.00 | 28% 18.07M to 23.07M | |
| 17-Jul-23 6:21 PM View: | Bilinsky Igor Chief Operating Officer | Iovance Biotherapeutics, Inc. (IOVA) | 14-Jul-23 | Option Exercise | 2,813 | -- | -- | 11% 25.8K to 28.61K | |
| 17-Jul-23 6:21 PM View: | Bilinsky Igor Chief Operating Officer | Iovance Biotherapeutics, Inc. (IOVA) | 14-Jul-23 | Payment of Exercise | 1,395 | $7.76 | $10,825.20 | (5%) 28.61K to 27.21K | |
| 17-Jul-23 6:22 PM View: | Graf Finckenstein Friedrich Chief Medical Officer | Iovance Biotherapeutics, Inc. (IOVA) | 14-Jul-23 | Option Exercise | 2,813 | -- | -- | 10% 29.54K to 32.35K | |
| 17-Jul-23 6:22 PM View: | Vogt Frederick G Interim CEO & General Counsel | Iovance Biotherapeutics, Inc. (IOVA) | 14-Jul-23 | Option Exercise | 20,834 | -- | -- | 34% 60.87K to 81.7K | |
| 17-Jul-23 6:22 PM View: | Graf Finckenstein Friedrich Chief Medical Officer | Iovance Biotherapeutics, Inc. (IOVA) | 14-Jul-23 | Payment of Exercise | 1,395 | $7.76 | $10,825.20 | (4%) 32.35K to 30.95K | |
| 17-Jul-23 6:22 PM View: | Vogt Frederick G Interim CEO & General Counsel | Iovance Biotherapeutics, Inc. (IOVA) | 14-Jul-23 | Payment of Exercise | 8,851 | $7.76 | $68,683.80 | (11%) 81.7K to 72.85K | |
| 18-Apr-23 5:48 PM View: | Bilinsky Igor Chief Operating Officer | Iovance Biotherapeutics, Inc. (IOVA) | 14-Apr-23 | Option Exercise | 2,812 | -- | -- | 12% 24.38K to 27.19K | |
| 18-Apr-23 5:49 PM View: | Graf Finckenstein Friedrich Chief Medical Officer | Iovance Biotherapeutics, Inc. (IOVA) | 14-Apr-23 | Payment of Exercise | 1,395 | $5.64 | $7,867.80 | (5%) 30.93K to 29.54K | |
| 18-Apr-23 5:50 PM View: | Vogt Frederick G Interim CEO & General Counsel | Iovance Biotherapeutics, Inc. (IOVA) | 14-Apr-23 | Payment of Exercise | 8,851 | $5.64 | $49,919.60 | (13%) 69.72K to 60.87K | |
| 18-Apr-23 5:49 PM View: | Graf Finckenstein Friedrich Chief Medical Officer | Iovance Biotherapeutics, Inc. (IOVA) | 14-Apr-23 | Option Exercise | 2,812 | -- | -- | 10% 28.12K to 30.93K | |
| 18-Apr-23 5:50 PM View: | Vogt Frederick G Interim CEO & General Counsel | Iovance Biotherapeutics, Inc. (IOVA) | 14-Apr-23 | Option Exercise | 20,834 | -- | -- | 43% 48.88K to 69.72K | |
| 18-Apr-23 5:48 PM View: | Bilinsky Igor Chief Operating Officer | Iovance Biotherapeutics, Inc. (IOVA) | 14-Apr-23 | Payment of Exercise | 1,395 | $5.64 | $7,867.80 | (5%) 27.19K to 25.8K | |
| 19-Jan-23 4:52 PM View: | Graf Finckenstein Friedrich Chief Medical Officer | Iovance Biotherapeutics, Inc. (IOVA) | 17-Jan-23 | Option Exercise | 11,248 | -- | -- | 52% 21.55K to 32.8K | |
| 19-Jan-23 4:51 PM View: | Vogt Frederick G Interim CEO & General Counsel | Iovance Biotherapeutics, Inc. (IOVA) | 17-Jan-23 | Option Exercise | 83,325 | -- | -- | 4166% 2.0K to 85.33K | |
| 19-Jan-23 4:52 PM View: | Bilinsky Igor Chief Operating Officer | Iovance Biotherapeutics, Inc. (IOVA) | 17-Jan-23 | Payment of Exercise | 4,671 | $6.43 | $30,034.50 | (16%) 29.05K to 24.38K | |
| 19-Jan-23 4:52 PM View: | Bilinsky Igor Chief Operating Officer | Iovance Biotherapeutics, Inc. (IOVA) | 17-Jan-23 | Option Exercise | 11,248 | -- | -- | 63% 17.8K to 29.05K | |
| 19-Jan-23 4:52 PM View: | Graf Finckenstein Friedrich Chief Medical Officer | Iovance Biotherapeutics, Inc. (IOVA) | 17-Jan-23 | Payment of Exercise | 4,678 | $6.43 | $30,079.50 | (14%) 32.8K to 28.12K | |
| 19-Jan-23 4:51 PM View: | Vogt Frederick G Interim CEO & General Counsel | Iovance Biotherapeutics, Inc. (IOVA) | 17-Jan-23 | Payment of Exercise | 36,441 | $6.43 | $234,316.00 | (43%) 85.33K to 48.88K | |
| 05-Jan-23 10:00 PM View: | Bilinsky Igor Chief Operating Officer | Iovance Biotherapeutics, Inc. (IOVA) | 03-Jan-23 | Payment of Exercise | 10,553 | $6.11 | $64,478.80 | (37%) 28.35K to 17.8K | |
| 05-Jan-23 10:00 PM View: | Bellemin Jean-Marc Chief Financial Officer | Iovance Biotherapeutics, Inc. (IOVA) | 03-Jan-23 | Option Exercise | 18,850 | -- | -- | 198% 9.5K to 28.35K | |
| 05-Jan-23 10:00 PM View: | Bilinsky Igor Chief Operating Officer | Iovance Biotherapeutics, Inc. (IOVA) | 03-Jan-23 | Option Exercise | 18,850 | -- | -- | 198% 9.5K to 28.35K |
